Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 5.5% – What’s Next?

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s stock price fell 5.5% during trading on Wednesday . The company traded as low as $16.02 and last traded at $16.10. 126,873 shares traded hands during trading, a decline of 37% from the average session volume of 202,334 shares. The stock had previously closed at $17.04.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a report on Tuesday, November 12th.

Pulse Biosciences Price Performance

The stock’s 50-day moving average price is $17.24 and its two-hundred day moving average price is $15.25.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same period in the previous year, the firm earned ($0.19) EPS.

Hedge Funds Weigh In On Pulse Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets lifted its stake in Pulse Biosciences by 63.6% during the 1st quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock valued at $66,000 after acquiring an additional 2,952 shares during the period. Quest Partners LLC bought a new position in Pulse Biosciences during the 2nd quarter valued at about $91,000. Price T Rowe Associates Inc. MD bought a new position in Pulse Biosciences during the 1st quarter valued at about $88,000. Cetera Advisors LLC bought a new position in Pulse Biosciences during the 1st quarter valued at about $109,000. Finally, Creative Planning lifted its stake in Pulse Biosciences by 113.9% during the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after acquiring an additional 11,667 shares during the period. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.